INTIInhibitor Therapeutics Inc.

About Inhibitor Therapeutics Inc. (INTI)

Inhibitor Therapeutics Inc. (INTI) is a Biotechnology company headquartered in Tampa, FL, United States whose shares trade over-the-counter on the OTCQB tier.

Inhibitor Therapeutics is a biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers

Products and services

We are a clinical-stage pharmaceutical company focused on differentiated and patent-protected products that address unmet clinical needs. Our lead indication is for a hereditary, orphan indication called Gorlin’s syndrome (Basal Cell Carcinoma Nevus Syndrome) or BCCNS. This cancer syndrome is characterized by the development of numerous basal cell carcinomas all over the body starting around the time of puberty and continuing lifelong, but especially in sun-exposed areas like the face and neck. There is no approved pharmaceutical treatment for this indication. Management consists of repeated surgical excisions of basal cell carcinomas in this syndrome often times leading to disfigurement. In a phase 2b study of 447 surgically-eligible tumors the use of itraconazole resulted in an objective response consisting of over 50% of tumors shrinking or disappearing, the balance of lesions stabilized, and only 7 lesions that grew in size.

INTI key facts

Ticker symbol

INTI

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Tampa, FL, United States

Country of incorporation

US

Employees

6

Estimated market cap

$8.67M (as of Apr 11, 2025)

Shares outstanding

172,573,545

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Inhibitor Therapeutics Inc. leadership

• Francis Edward O'Donnell — CEO
• James A. McNulty — CFO, Treasurer, Secretary
• Simon Isaac Bettink — Director, Ops.

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with I